News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
797,626 Results
Type
Article (60744)
Company Profile (686)
Press Release (736177)
Multimedia
Podcasts (154)
Webinars (22)
Section
Business (220255)
Career Advice (2882)
Deals (38322)
Drug Delivery (145)
Drug Development (87582)
Employer Resources (188)
FDA (18054)
Job Trends (16456)
News (376293)
Policy (37790)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2953)
Academic (1)
Accelerated approval (36)
Adcomms (35)
Allergies (156)
Alliances (54422)
ALS (184)
Alzheimer's disease (1795)
Antibody-drug conjugate (ADC) (356)
Approvals (18267)
Artificial intelligence (612)
Autoimmune disease (177)
Automation (43)
Bankruptcy (392)
Best Places to Work (12444)
BIOSECURE Act (23)
Biosimilars (210)
Biotechnology (429)
Bladder cancer (168)
Brain cancer (66)
Breast cancer (679)
Cancer (5160)
Cardiovascular disease (456)
Career advice (2444)
Career pathing (42)
CAR-T (309)
CDC (63)
Celiac Disease (2)
Cell therapy (826)
Cervical cancer (39)
Clinical research (74382)
Collaboration (1880)
Company closure (5)
Compensation (1218)
Complete response letters (76)
COVID-19 (2983)
CRISPR (104)
C-suite (924)
Cystic fibrosis (151)
Data (6486)
Decentralized trials (2)
Denatured (46)
Depression (155)
Diabetes (542)
Diagnostics (7183)
Digital health (52)
Diversity (13)
Diversity, equity & inclusion (47)
Drug discovery (295)
Drug pricing (225)
Drug shortages (35)
Duchenne muscular dystrophy (249)
Earnings (94853)
Editorial (67)
Employer branding (21)
Employer resources (163)
Events (126814)
Executive appointments (1047)
FDA (21361)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1586)
Gene editing (222)
Generative AI (58)
Gene therapy (675)
GLP-1 (1123)
Government (5303)
Grass and pollen (7)
Guidances (387)
Healthcare (20494)
HIV (66)
Huntington's disease (51)
IgA nephropathy (89)
Immunology and inflammation (295)
Immuno-oncology (70)
Indications (122)
Infectious disease (3292)
Inflammatory bowel disease (214)
Inflation Reduction Act (15)
Influenza (128)
Intellectual property (265)
Interviews (508)
IPO (17550)
IRA (59)
Job creations (4406)
Job search strategy (2021)
JPM (70)
Kidney cancer (17)
Labor market (91)
Layoffs (636)
Leadership (42)
Legal (9421)
Liver cancer (99)
Longevity (16)
Lung cancer (696)
Lymphoma (391)
Machine learning (43)
Management (64)
Manufacturing (884)
MASH (177)
Medical device (14798)
Medtech (14860)
Mergers & acquisitions (21866)
Metabolic disorders (1425)
Multiple sclerosis (173)
NASH (20)
Neurodegenerative disease (361)
Neuropsychiatric disorders (106)
Neuroscience (3162)
Neurotech (1)
NextGen: Class of 2026 (7398)
Non-profit (5001)
Now hiring (68)
Obesity (690)
Opinion (335)
Ovarian cancer (171)
Pain (222)
Pancreatic cancer (240)
Parkinson's disease (306)
Partnered (34)
Patents (537)
Patient recruitment (525)
Peanut (63)
People (63376)
Pharmaceutical (132)
Pharmacy benefit managers (34)
Phase 1 (23138)
Phase 2 (32471)
Phase 3 (24382)
Pipeline (5673)
Policy (343)
Postmarket research (3052)
Preclinical (9930)
Press Release (71)
Prostate cancer (256)
Psychedelics (56)
Radiopharmaceuticals (307)
Rare diseases (954)
Real estate (6748)
Recruiting (75)
Regulatory (27933)
Reports (59)
Research institute (2682)
Resumes & cover letters (470)
Rett syndrome (28)
RNA editing (19)
RSV (90)
Schizophrenia (164)
Series A (259)
Series B (204)
Service/supplier (26)
Sickle cell disease (106)
Special edition (28)
Spinal muscular atrophy (173)
Sponsored (46)
Startups (4057)
State (2)
Stomach cancer (21)
Supply chain (114)
Tariffs (100)
The Weekly (106)
Vaccines (1163)
Venture capital (99)
Weight loss (476)
Women's health (98)
Worklife (21)
Date
Today (174)
Last 7 days (745)
Last 30 days (2555)
Last 365 days (31992)
2026 (4455)
2025 (32403)
2024 (37556)
2023 (42123)
2022 (53467)
2021 (58244)
2020 (57115)
2019 (50374)
2018 (38331)
2017 (35501)
2016 (35571)
2015 (41399)
2014 (35451)
2013 (30843)
2012 (32967)
2011 (33530)
2010 (31680)
Location
Africa (1008)
Alabama (91)
Alaska (7)
Arizona (334)
Arkansas (15)
Asia (46588)
Australia (7740)
California (11859)
Canada (3387)
China (1197)
Colorado (500)
Connecticut (514)
Delaware (356)
Europe (103305)
Florida (1766)
Georgia (381)
Hawaii (4)
Idaho (64)
Illinois (950)
India (75)
Indiana (552)
Iowa (24)
Japan (452)
Kansas (133)
Kentucky (44)
Louisiana (29)
Maine (72)
Maryland (1487)
Massachusetts (8653)
Michigan (345)
Minnesota (661)
Mississippi (6)
Missouri (142)
Montana (36)
Nebraska (28)
Nevada (130)
New Hampshire (85)
New Jersey (3159)
New Mexico (32)
New York (3124)
North Carolina (1606)
North Dakota (10)
Northern California (5734)
Ohio (354)
Oklahoma (23)
Oregon (52)
Pennsylvania (2369)
Puerto Rico (25)
Rhode Island (51)
South America (1388)
South Carolina (70)
South Dakota (1)
Southern California (4596)
Tennessee (181)
Texas (1849)
United States (42447)
Utah (354)
Vermont (1)
Virginia (294)
Washington D.C. (87)
Washington State (980)
West Virginia (4)
Wisconsin (135)
Wyoming (2)
797,626 Results for "astellas pharma us inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Patents
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
February 18, 2026
·
4 min read
·
Shawna Williams
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
Drug pricing
UK Agrees To Boost Drug Spending by 25% To Avoid US Pharma Tariffs
U.K.-based pharmas will not face tariffs as long as Donald Trump is president, according to the agreement.
December 1, 2025
·
1 min read
·
Annalee Armstrong
In partnership with PII
Bridging Formulation and Device: Integrated Supply Chain Strategies for U.S. Pharma Manufacturing
The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development with drug delivery device design—and leveraging a single‐vendor ecosystem—can deliver significant time, cost, and regulatory advantages for US‑focused drug products, according to industry experts.
December 8, 2025
·
5 min read
·
Jennifer Smith-Parker
Press Releases
MAIA Pharmaceuticals Selected by Asahi Kasei Pharma to Advance Teribone™ for US Osteoporosis Patients
February 19, 2026
·
4 min read
Press Releases
Dexcel Pharma USA Acquires US Rights to Zubsolv®
January 8, 2026
·
1 min read
Press Releases
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
February 17, 2026
·
4 min read
Press Releases
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
February 11, 2026
·
6 min read
Press Releases
LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
January 29, 2026
·
3 min read
Press Releases
Pharmaceutical Service Provider Vetter Pharma to Build New Manufacturing Site in Germany
Strategic Investments in the EU and US strengthen Vetter’s Global Footprint • Building permit application for German site submitted • Construction start is scheduled for the 2nd quarter 2026, with operational readiness in 2031 • Expansions in the US and Europe are included in a €1.5 billion investment plan
January 29, 2026
·
1 min read
1 of 79,763
Next
